Response and progression in recurrent malignant glioma

Kenneth R. Hess, Eric T. Wong, Kurt A. Jaeckle, Athanassios P. Kyritsis, Victor A. Levin, Michael D. Prados, W. K.Alfred Yung

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

In this article we report the results of a study of the relationship between response and progression in 375 patients with recurrent glioma enrolled in phase II chemotherapy trials. We reviewed the records of patients from 8 consecutive phase II trials, including 225 patients with recurrent glioblastoma multiforme and 150 with recurrent anaplastic astrocytoma. Median age was 45 years (range, 15-82) and median Karnofsky performance score was 80 (range, 60-100). Forty-one patients (11%) had more than two prior resections and/or more than two prior chemotherapy regimens. Best response was complete (n = 1) or partial (n = 33) in 34 patients (9%). Median time to response was 14 weeks, and median response duration was 44 weeks. Simon-Makuch estimates for 52-week progression-free survival for patients progression-free at 13 weeks were 48% for response and 28% for nonresponse. When response was treated as a time-dependent covariate in a Cox proportional hazards regression analysis, response was associated with significantly lower failure rates (hazard ratio 0.5; 95% confidence interval 0.3-0.8; P = 0.0016). This study showed that response in recurrent glioma is associated with a significant reduction in progression rates.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalNeuro-oncology
Volume1
Issue number4
DOIs
StatePublished - Oct 1999

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Fingerprint Dive into the research topics of 'Response and progression in recurrent malignant glioma'. Together they form a unique fingerprint.

  • Cite this

    Hess, K. R., Wong, E. T., Jaeckle, K. A., Kyritsis, A. P., Levin, V. A., Prados, M. D., & Yung, W. K. A. (1999). Response and progression in recurrent malignant glioma. Neuro-oncology, 1(4), 282-288. https://doi.org/10.1215/15228517-1-4-282